.png "Atricure (NASDAQ: ATRC)")
In a report released yesterday, Jason Mills from Canaccord Genuity maintained a Buy rating on Atricure (ATRC), with a price target of $51.00. The company’s shares closed last Monday at $43.16, close to its 52-week high of $44.51.
According to TipRanks.com, Mills is a top 100 analyst with an average return of 23.1% and a 70.7% success rate. Mills covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Irhythm Technologies, and Intuitive Surgical.
Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $45.33, implying a 3.7% upside from current levels. In a report issued on February 5, BTIG also initiated coverage with a Buy rating on the stock with a $42.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $44.51 and a one-year low of $22.57. Currently, Atricure has an average volume of 256.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
